Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Says SBOMs Are Key To Better Cybersecurity In NIST Report

Executive Summary

The US regulator’s report is meant to help develop new federal cybersecurity purchasing guidelines that could eventually be used to implement a cybersecurity consumer labeling program.

You may also be interested in...



Cybersecurity Guidance Update Lays Out ‘Cyber Device’ Rules

Draft guidance from the US Food and Drug Administration details what the agency wants to see to demonstrate cybersecurity in connected devices during premarket submissions. 

NIST Cybersecurity Framework 2.0 Expands Guidance’s Scope, Introduces ‘Govern’ Function

NIST released the second version of its Cybersecurity Framework, emphasizing the importance of cybersecurity across sectors.

Digital Health Roundup, May 2021: Immersive Technologies In Surgery Suite, ‘Smart’ Toilets And Pills; New SaMD Cybersecurity Standards

In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from May.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel